Cemiplimab plus OSE2101 as maintenance after chemo-immunotherapy for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (cemiplimab and OSE2101) as ongoing treatment after initial chemo-immunotherapy for advanced lung cancer. It is for patients whose tumor DNA is still detectable in the blood, and who carry a specific immune marker called HLA-A2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) that cannot be removed by surgery.
- You are about to start or have recently started your first treatment with chemotherapy plus immunotherapy.
- You must have a specific genetic marker called HLA-A2 (a blood test can check this).
- Your general health is good enough to be up and about (ECOG score 0 or 1).
- You do not have certain gene changes (EGFR, ALK, ROS1) in your tumor.
- You have not had another cancer in the last 3 years, except for some skin cancers or early-stage cervical, breast, or bladder cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
This trial tests a personalized chemotherapy approach for people with early-stage (stage II–IIIB) non-small cell lung cancer that can be removed with surgery. It uses the tumor's PD-L1 level (a marker that helps the immune system attack cancer) to guide treatment before surgery, aiming to improve outcomes.
This study tests a combination of an immunotherapy drug (cemiplimab) plus chemotherapy for advanced squamous non-small cell lung cancer. Researchers want to see if this treatment works better in people whose tumors have a certain enzyme level.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a combination of immunotherapy (cemiplimab) and chemotherapy for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. It looks at whether this treatment works better when certain immune cells in the blood are high.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.